Earnings Call · Q1 FY2022·2022-05-05

Q1 22EPS +90.91%·Rev n/aQ4 21EPS +100.00%*·Rev n/aQ3 21EPS -100.00%*·Rev n/aQ2 21EPS +100.00%*·Rev n/a⚠ consensus missing

PUMA BIOTECHNOLOGY, INC. PBYI

Mariann Ohanesian — Senior Director of Investor Relations

Alan Auerbach — Chief Executive Officer, President and Chairman of the Board

Jeffrey Ludwig — Commercial Leader (inferred from commercial review context)

Maximo Nougues — Chief Financial Officer

−11.4%1d on move date−10.8% vs SPY3d−18.8%5d−21.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PBYI calls or request research access.

More PBYI calls Browse calls Request research access